Subbiah et al. investigated the intracranial efficacy of selpercatinib, and observed an ORR of 82% and an CR of 23% among 22 patients with measurable intracranial disease, showing a robust and durable intracranial efficacy in RET fusion-positive NSCLC patients (17). The gene discussed is RET; the disease is non-small cell lung carcinoma.